MapLight Therapeutics

Update in progress

MPLT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

MapLight Therapeutics, Inc. is a clinical-stage biopharma focused on central nervous system disorders. Its programs include ML-007C-MA, an M1/M4 muscarinic agonist for schizophrenia and Alzheimer’s disease psychosis; ML-004 for social communication deficits and irritability in autism; ML-021 for motor symptoms in Parkinson’s disease; ML-055 for neuropsychiatric conditions; and ML-009, a GPR52 allosteric modulator for hyperactivity and agitation disorders. It also targets neural circuits for therapy. Formerly Alvarado Therapeutics, renamed in 2019. Founded 2018, Redwood City, CA.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive